Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Sunday's Featured Story The 3 Penny Stocks You Swore You'd Never Buy (But You'll Check Anyway)By Chris Markoch. Article Posted: 1/18/2026. 
At a Glance - Vaxart is a clinical-stage biotech developing oral vaccines that could transform global immunization if its platform proves effective.
- Microvision develops cost-effective lidar technology for autonomous vehicles, with upside tied to industry adoption and potential partnerships.
- Datavault AI focuses on monetizing digital data through AI and blockchain tools, offering speculative exposure to the emerging data-as-an-asset theme.
Penny stocks attract speculative investors seeking high-risk, high-reward opportunities. They often involve companies with disruptive technologies, participation in emerging trends, or compelling turnaround stories. Many of these firms will never scale or survive, but if one does, the returns can be impressive. For investors who believe strength lies in numbers, MarketBeat offers a tool that lists the 100 Most Popular Penny Stocks, based on the number of MarketBeat subscribers following each company. While popularity isn't a guarantee of success, it can lend additional conviction to an investment thesis. A little-known government task force just wrapped up a 20-year project, and its findings could unlock access to a massive U.S. national asset. Under existing law, everyday Americans may now have a legal path to participate in what some are calling a once-in-a-generation opportunity.
Details are still flying under the radar, but that may not last. See the full briefing and how it works Some investors define a penny stock as any equity trading for $5 or less. This screener uses the traditional definition: stocks priced below $1. These stocks are highly volatile; do your own research and know your risk tolerance before taking a position. Vaxart: A Potential Game-Changer for Global Immunization Efforts Vaxart Inc. (NASDAQ: VXRT) is a clinical-stage biotechnology company developing oral vaccines for infectious diseases, including influenza, norovirus and COVID-19. Unlike traditional injectable vaccines, Vaxart's tablet-based platform aims to simplify distribution and improve global accessibility. The bull case for Vaxart centers on its innovative delivery approach. If the company can secure FDA approval and successfully scale manufacturing and distribution, its oral vaccines could reduce logistical barriers to mass immunization and open the door to significant licensing partnerships. Positive trial results or a commercial collaboration could dramatically shift sentiment and valuation from the stock's current low base. Clinical development is the largest risk. Vaxart has not yet commercialized a product, and vaccine development is costly and unpredictable. Competition from established players with much larger R&D budgets also limits visibility. For now, Vaxart is primarily a long-term speculative bet on platform validation rather than near-term profitability. The MarketBeat analyst coverage for Vaxart is minimal—only a single analyst— which, while not uncommon for microcap names, should prompt caution. VXRT also has only about 18% institutional ownership. On a more positive note, short interest is roughly 2%, which may limit some short-driven volatility. Microvision: Developing Cost-Effective LiDAR Units for Autonomous Driving Microvision Inc. (NASDAQ: MVIS) develops LiDAR (light detection and ranging) sensors used in autonomous vehicles, smart infrastructure and industrial sensing. The company's hardware and software solutions enable precise 3D mapping needed for self-driving and advanced driver-assistance systems (ADAS). Microvision focuses on creating compact, cost-effective LiDAR units that could appeal to automakers seeking scalable sensor solutions. The bull case for Microvision rests on continued progress toward vehicle automation and the potential to secure partnerships with major automotive manufacturers. If the company can demonstrate performance or cost advantages, it might win supply agreements or licensing deals that materially improve revenue visibility. Microvision's technology also has potential applications beyond vehicles—robotics and smart cities among them—adding optionality to its growth story. Despite the promise, Microvision faces stiff competition from LiDAR rivals such as Luminar (NASDAQ: LAZR), Innoviz (NASDAQ: INVZ) and Ouster (NYSE: OUST). The path to profitability is unclear, and repeated delays in widespread commercial adoption of LiDAR have frustrated investors. MVIS is covered by three analysts and carries a consensus price target of $2.50—a roughly 169% increase from its Jan. 15 closing price. Like many speculative names, Microvision has relatively low institutional ownership (about 30%) and elevated short interest (around 21%), meaning investors should expect high volatility. Datavault AI: Trying to Democratize Data Ownership Datavault AI Inc. (NASDAQ: DVLT) operates at the intersection of artificial intelligence, data monetization and digital asset management. The company helps organizations turn raw data into tradable, revenue-generating assets through its patented Datavault platform. By combining AI, blockchain and analytics tools, Datavault AI aims to democratize data ownership and unlock monetization opportunities that traditional systems overlook. The bullish thesis for Datavault AI rests on its niche focus and scalability potential. As data becomes increasingly valuable, businesses—and even individuals—are seeking safe ways to monetize digital information. Datavault's technology could benefit from broader AI adoption and rising interest in data sovereignty. Early-stage traction or strategic partnerships could catalyze investor confidence. That said, Datavault AI operates in a highly experimental space. Its business model is still evolving, and a clear path to meaningful revenue is unproven. Institutional ownership is under 1%, and short interest exceeds 16% at the time of writing. Investors considering DVLT should view it as a long-term, speculative position based on belief in data-as-an-asset innovation rather than near-term earnings potential.
| 
